stem cell engineering
DOI:
https://doi.org/10.51481/amc.v47i2.181Keywords:
Célula madre, Stem cell, hematopoyesis, trasplante de células hematopoyéticas, sangre de cordón umbilical, clonación, transferencia de núcleos, clonación terapéutica, clonación reproductiva, plasticidadAbstract
Stem cell engineering is a technology applicable to thesolution of health problems of human beings, regarding par-ticularly tissue reconstruction and the reestablishment ofnormal cell function in metabolic, hematological, immuno-logical and degenerative disorders.
Research of stem cell biology has led to the recognitionof its own identity and to establish a group of cells of dif-ferent origin that share characteristics of self renovation andplasticity. This group encompasses embryonal, mesenchy-mal, hematopoietical , umbilical and other cells that residein tissues such as neuronal stem cells.
Investigation of embryonal stem cells and the proce-dures of reproductive clonation and nuclear transplant havetriggered an ethic debate, of political and religious aspects.We can only voice our opinion if we know the basic princi-ples of the biology and engineering of stem cells.
Downloads
References
Rosenthal N. Prometheus s vulture and the stem-cell promise. N EnglJ Med 2003; 349:267-274.
Garrido Colino C. Estado actual de la investigación con célulasmadre. An Pediatr (Barc) 2003; 59:552-558.
Sylvester KG, Longaker MT. Stem cells: review and update. ArchSurg 2004; 139:93-99.
Blau HM, Brazelton TR, Weimann JM. The evolving concept of astem cell: entity or function? Cell 2001; 105:829-841.
van der Kooy D, Weiss S. Why stem cells? Science 2000; 287:1439-
Evans MJ, Kaufman MH. Establishment in culture of pluripotentialstem from mouse embryos. Nature 1981; 292:154-156.
Bradley A, Evans M, Kaufman MH, Robertson E. Formation ofgerm-like chimaeras from embryo-derived teratocarcinoma cell lines.Nature 1984; 309:255-256.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, SwiergielJJ, Marshall VS, et al. Embryonic stem cell lines derived from humanblastocysts. Science 1998; 282:1145-1147.
Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viableoffspring derived from fetal and adult mammalian cells. Nature 1997;385:810-813.
Hochedlinger K, Jaenisch R. Nuclear transplantation, embryonicstem cells, and the potential for cell therapy. N Engl J Med 2003;349:275-286.
Lisker R. Ethical and legal issues in therapeutic cloning and the studyof stem cells. Arch Med Res 2003; 34:607-611.
Rideout WMIII, Hochedlinger K, Kyba M Daley GO Jaenisch.Correction of a genetic defect by nuclear transplantation and com-bined cell and gene therapy. Cell 2002; 109:17-27.
Gurdon JB, Byrne JA, Simonsson S. Nuclear reprogramming andstem cell creation. Proc Natl Acad Sci USA 2003; 100:11819-11822.
Selkirk SM. Gene therapy in clinical medicine. Postgrad Med J 2004;80:560-570.
Cavazzana-Calvo M, Hacein-Bey-Abina S, de Saint BG, Gross F,Yvon E, Nusbaum P, et al. Gene therapy of human severe combinedimmunodeficiency (SCID)-X1 disease. Science 2000; 288:669-672.
Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, deVillartay JP, et al. Sustained correction of X-linked severe combinedimmunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-1193.
Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al.Correction of ADA-SCID by stem cell gene therapy combined withnonmyeloablative conditioning. Science 2002; 296:2410-2413
Nathwani AC, Davidoff AM, Linch DC. A review of gene therapy forhaematological disorders. Br. J Haematol 2005; 128:3-17.
Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP,Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell prolif-eration in two patients after gene therapy for SCID-X1. Science 2003;302:415-419.
Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, WulffraatN, McIntyre E, et al. A serious adverse event after successful genetherapy for X-linked severe combined immunodeficiency. N Engl JMed 2003; 348: 255-256.
McCormack MP, Rabbitts TH. Activation of the T-cell oncogeneLMO2 after gene therapy for X-linked severe combined immunode-ficiency. N Engl J Med 2004; 350:913-922.
Horwitz EM. Stem cell plasticity: the growing potential of cellulartherapy. Arch Med Res 2003; 34:600-606.
Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S,Gardner R, et al. Multi-organ, multi-lineage engraftment by a singlebone marrow-derived stem cell. Cell 2001; 105:369-377.
Wurmser AE, Gage FH. Stem cells: cell fusion causes confusion.Nature 2002; 416:485-487.
Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, etal. Bone marrow cells adopt the phenotype of other cells by sponta-neous cell fusion. Nature 2002; 416:542-545.
Ying QIL, Nichols J, Evans EP, Smith AG. Changing potency byspontaneous fusion. Nature 2002; 416:545-548.
Szilvassy SJ. The biology of hematopoietic stem cells. Arch Med Res2003; 34:446-460.
Baron F, Storb R, Little MT. Hematopoietic cell transplantation: fivedecades of progress. Arch Med Res 2003; 34:528-544.
Mayani H, Lansdorp PM. Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 1998;16:153-165.
Wognum AW, Eaves AC, Thomas TE. Identification and isolation ofhematopoietic stem cells. Arch Med Res 2003; 34:461-475.
Cohen Y, Nagler A. Cord blood biology and transplantation. IMAJ2004; 6:39-46.
Mayani H, Alvarado-Moreno JA, Flores-GuzmanP. Biology ofhuman hematopoietic stem and progenitor cells present in circulation.Arch Med Res 2003; 34:476-488.
Summer R, Kotton DN, Liang S, Fitzsimmons K, Sun X, Fine A.Embryonic lung side population cells are hematopoietic and vascularprecursors. Am J Respir Cell Mol Biol 2005; (en prensa).
Hwang WS, Ryu YJ, Park JH, Park ES, Lee EG, Koo JM, et al.Evidence of a pluripotent human embryonic stem cell line derivedfrom a cloned blastocyst. Science 2004; 303:1669-1674.
Cowan CA, Klimanskaya I, McMahon J, Atienza J, Witmyer J,Zucker JP, et al. Derivation of embryonic stem-cell lines from humanblastocysts. N Engl J Med 2004; 350:1353-1356.
Phimister EG, Drazen JM. Two fillips for human embryonic stemcells. N Engl J Med 2004; 350:1351-1352.
Tuch BE, Scott H, Armati PJ, Tabiin MT, Wang LP. Use of humanfetal tissue for biomedical research in Australia, 1994-2002. Med JAust 2003; 179:547-550.74
Landry DW, Zucker HA. Embryonic death and the creation of humanembryonic stem cells. J Clin Invest 2004; 114:1184-1186.
Sandel MJ. Embryo ethics - The moral logic of stem-cell research. NEngl J Med 2004; 351:207-209.
McHugh PR. Zygote and ""clonote"" - The ethical use of embryonicstem cells. N Engl J Med 2004; 351:209-211.
Kiessling AA. Eggs alone. Human parthenotes: an ethical source ofstem cells for therapies? Nature 2005; 434:145.
Weimann JM, Charlton CA, Brazelton TR, Hackman RC, Blau HM.Contribution of transplanted bone marrow cells to Purkinje neuronsin human adult brains. Proc Natl Acad Sci USA 2003; 100:2088-2093.
Quaini F, Urbanek K, Beltrami AP, Finato N, Beltami CA, Nadal-Ginard B, et al. Chimerism of the transplanted heart. N Engl J Med2002; 346:5-15.
Gluckman E, Rocha V, Chastang C, Eurocord-Cord Blood TransplantGroup. Cord blood hamtopoietic stem cells biology and transplanta-tion. Hematology 1998; 1:1-14.
Sirchia G, Rebulla P. Placental/umbilical cord blood transplantation.Haematologica 1999; 84:738-747.
Lewis ID. Clinical and experimental uses of umbilical cord blood. IntMed J 2002; 32:601-609.
Rocha V, Sanz G, Gluckman E, Eurocord and European blood andmarrow transplant group. Umbilical cord blood transplantation. CurrOpin Hematol 2004; 11:375-385.
Gluckman E. Ex vivo expansion of cord blood cells. Exp Hematol2004; 32:410-412.
Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al.Mesenchymal stem cell in the Wharton s jelly of the human umbili-cal cord. Stem Cells 2004; 22:1330-1337.
Arai S, Klingemann HG. Hematopoietic stem cell transplantation:bone marrow vs. mobilized peripheral blood. Arch Med Res 2003;34:545-553.
Daley GQ, Goodell MA, Snyder EY. Realistic prospect for stem celltherapeutics. Hematology 2003; 1:398-418.
Stocum DL. Stem cells in CNS and cardiac regeneration. AdvBiochem Eng Biotechnol 2005; 93:135-159.
Gerritsen EJA, Vossen JM, Fasth A. Friedrich W, Morgan G, PorrasO. Bone marrow transplantation for autosomal recessive osteopetro-sis. A report from the Working Party on Inborn Errors of the EuropeanBone Marrow Transplantation Group. J Pediatr 1994; 125:896-902.
Porras O. Trasplante de Médula Osea.. Rev Méd Hosp Nal NiñosCosta Rica 1993; 26-28(NE):55-76.
Weissman IL. Translating stem and progenitor cell biology to theclinic: barriers and opportunities. Science 2000; 287:1442-1446.
Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cordblood transplants). Hematology 2004; 1:354-371.
Benito AI, Diaz MA, González-Vicent M, Sevilla J, Madero L.Hematopoietic stem cell transplantation using umbilical cord bloodprogenitors: review of current clinical results. Bone Marrow Transp2004; 33:675-690.
Barker JN, Wagner JE. Umbilical-cord blood transplantation for thetreatment of cancer. Nature 2003; 3:526-532.
Burgio GR, Gluckman E, Locatelli F. Ethical reappraisal of 15 yearsof cord-blood transplantation. Lancet 2003; 361:250-252.
Davey S, Armitage S, Rocha V, Garnier F, Brown J, Brown CJ, et al.The London Cord Blood Bank: analysis of banking and transplanta-tion outcome. Br J Haematol 2004; 125:358-365.
Gluckman E, Eurocord Netcord Organization. Ethical and legalaspects of placental/cord blood banking and transplant. Hematol J2000; 1:67-69.
Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, StornaiuoloA, Cossu G, et al. Muscle regeneration by bone marrow-derived myo-genic progenitors. Science 1998; 279:1528-1530.
Ferrari G, Mavilio F. Myogenic stem cells from the bone marrow: atherapeutic alternative for muscular distrophy? Neuromuscul Disord2002; 12 (S1):7-10.
Brazelton TR, Rossi FM, Keshet GI, Blau HM. From marrow tobrain: expression of neuronal phenotypes in adult mice. Science2000; 290:1775-1779.
Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK,Murase N, et al. Bone marrow as a potential source of hepatic ovalcells. Science 1999; 284:1168-1170.
Theise ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM,et al. Derivation of hepatocytes from bone marrow cells in mice afterirradiation-induced myeloablation. Hepatology 2000; 31:235-240.
Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R.Differentiation of embryonic stem cells to insulin-secreting structuressimilar to pancreatic islets. Science 2001; 292:1389-1394.
Smits AM, van Vliet P, Hassink RJ, Goumans MJ, Doevendans PA.The role of stem cells in cardiac regeneration. J Cell Mol Med 2005;9:25-36.
Yoon YS, Lee N, Scadova H. Myocardial regeneration with bone-marrow-derived stem cells. Biol Cell 2005; 97:253-263.
Kumar D, Kamp TJ, Lewinter MM. Embryonic stem cells: differen-tiation into cardiomyocytes and potential for heart repair and regen-eration. Coron Artery Dis 2005; 16:111-116.
Jain M, Pfister O, Hajjar RJ, Liao R. Mesenchymal stem cells in theinfarcted heart. Coron Artery Dis 2005; 16:93-97.
Pandur P. What does it take to make a heart? Biol Cell 2005; 97:197-210.
Wollert KC, Drexler H. Clinical applications of stem cells for theheart. Circ Res 2005; 96:151-163.
Menasche P. Skeletal myoblast for cell therapy. Coron Artery Dis2005; 16:105-110.75.Kh Haider H, Ashraf M. Bone marrow stem cells in the infarctedheart. Coron Artery Dis 2005; 16:99-103
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
